Objective: To evaluate the influence of the second course of the cell therapy on the dynamics of the non-motor symptoms in patients with PD 6 month after the therapy.
Background: The use of autologous mesenchymal multipotent stem cells (MSCs) is a promising area of cell therapy for Parkinson disease (PD). Our previous data demonstrate a decrease in the severity of motor and non-motor symptoms of the disease in the early post-transplant period but attenuation of these effects in the long-term follow-up. Our clinical study so far has included 13 PD patients that received only one course of the cell therapy and 10, who received the second course of the therapy during the long-term follow-up.The use of autologous mesenchymal multipotent stem cells (MSCs) is a promising area of cell therapy for Parkinson disease (PD). Our previous data demonstrate a decrease in the severity of motor and non-motor symptoms of the disease in the early post-transplant period but attenuation of these effects in the long-term follow-up. Our clinical study so far has included 14 PD patients that received only one course of the cell therapy and 10, who received the second course of the therapy during the long-term follow-up.
Method: MSCs were injected to ten patients with PD via two tandem (intranasal + intravenous) courses with an interval of 9-36 months between them. Effectiveness of the therapy was evaluated one, three and six months after the second course of the therapy according to the dynamics of non-motor symptoms by scoring the following scales: HDRS (Hamilton Depression Rating Scale), ESS (the Epworth Sleepiness Scale), NMSQ (Non-Motor Symptoms Questionnaire)
Results: We found a statistically significant decrease in the severity of non-motor symptoms after the second course of the therapy.
Conclusion: Positive results allow us to consider the repeated courses of the MSCs therapy as a disease-modifying therapeutic strategy in PD.
To cite this abstract in AMA style:
V. Chyzhyk, A. Boika, V. Ponomarev. Assessment of non-motor symptoms of Parkinson’s disease after the repeated courses of the autologous stem cell therapy [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/assessment-of-non-motor-symptoms-of-parkinsons-disease-after-the-repeated-courses-of-the-autologous-stem-cell-therapy/. Accessed May 9, 2025.« Back to 2023 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/assessment-of-non-motor-symptoms-of-parkinsons-disease-after-the-repeated-courses-of-the-autologous-stem-cell-therapy/